Comments
Shares of Lupin will remain in focus, following the company receiving approval from the USFDA for its generic version of Warner Chilcott’s oral contraceptive tablets Loestrin in two strengths. Lupin Pharmaceuticals Inc would shortly commence promotion of the product in the US. Warner Chilcott’s Loestrin Fe 1/20 had sales of $139.7 million and Loestrin Fe 1.5/30 $55.5 million in the year ended September, according to data from IMS Health.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.